CureVac (CVAC)
(Real Time Quote from BATS)
$5.41 USD
0.00 (0.00%)
Updated Aug 4, 2025 09:36 AM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, CureVac N.V. has a PEG ratio of 0.30 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.75.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CVAC 5.41 0.00(0.00%)
Will CVAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CVAC
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kamada (KMDA) Q1 Earnings Match Estimates
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Other News for CVAC
Bird flu emergency response ends as cases decline, CDC says
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
CureVac (CVAC) Downgraded by UBS with Lowered Price Target | CVAC Stock News
CureVac (CVAC) Downgraded by UBS as Acquisition Looms | CVAC Stock News
CureVac downgraded to Neutral from Buy at UBS